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Quantitative images of kidney 
function
Multiphoton fl uorescence microscopy allows noninvasive 
deep optical visualization of living tissues with minimal 
phototoxicity and high optical resolution. More 
importantly, dynamic processes and multiple functions 
of an intact organ can be visualized and quantifi ed in real 
time. With the use of this technique, glomerular fi ltration, 
proximal tubule endocytosis, apoptosis, microvascular 
function, protein expression, renal cysts, and major 
functions of the juxtaglomerular apparatus, including 
tubuloglomerular feedback (TGF) and renin release, have 
all been visualized and studied both in vivo and in vitro 
down to the subcellular level. In a new study, Kang et al. 
extend existing methods of multiphoton fl uorescence 
imaging to directly observe and quantify basic functional 
parameters of the kidney, including glomerular fi ltration 
rate (GFR) and permeability, blood fl ow, urinary 
concentration/dilution, and renin content and release, as 
well as more integrated and complex functions such as the 
TGF-mediated oscillations in glomerular fi ltration and 
tubular fl ow. Th ey fi nd that streptozotocin-induced diabetes 
almost doubled single-nephron GFR while increasing 
eightfold the glomerular permeability to a 70-kilodalton 
fl uorophore. Furosemide diluted and increased the volume 
of distal tubular fl uid, while also causing the release of 20% 
of juxtaglomerular renin content. Also, higher speeds of 
individual red blood cells were detected in intraglomerular 
capillaries as compared with peritubular vessels, and regular 
periods of glomerular contraction and relaxation were 
observed, resulting in oscillations of fi ltration and tubular 
fl ow rate. Oscillations in proximal and distal tubular fl ow 
showed cycle times similar to those of glomerular fi ltration 
(approximately 45 seconds), with a delay of approximately 
5–10 seconds and 25–30 seconds, respectively. Th ese 
innovative technologies provide the most complex, 
immediate, and dynamic portrayal of renal function, clearly 
depicting the components and mechanisms involved in 
normal physiology and pathophysiology. (Am J Physiol 
Renal Physiol 2006; 291: F495–F502)
Juan Oliver
Reversing the decline of academic 
medicine outside the United States
Th e ancient Greeks 
took medicine out 
of the realms of 
magic and gave it a 
scientifi c, ethical, 
and philosophical 
foundation. Th is 
approach continued 
into Roman times, 
lasting in all for 
about 500 years. With the death of Galen (ad 199) during 
the decline of the Roman Empire, the curtain came down on 
medical progress in Europe until the reawakening of critical 
scientifi c thought around the time that the Flemish anatomist 
Andreas Vesalius published his book De Humani Corporis 
Fabrica (1543).
Academic medicine in Europe has traditionally occupied 
a position of great strength but faces particular challenges; 
nowadays it consistently lags behind academic medicine 
in the United States, is increasingly challenged by India 
and China, and faces problems associated with expansion 
and integration. Th e most important sign of the poor state 
of academic medicine is a fall in recruitment to clinical 
academic posts in Europe during the past decade. Th is has 
led to the increased isolation of young clinicians from active 
research and the loss of scientists as models and mentors. Th e 
general public has deep concerns about the environmental 
safety of so-called progress in medicine. DJ Sheridan, in 
Lancet,1 and J Kaiser, in Science,2 indicate that change is 
urgently needed. Th eir proposals include the following:
•  Create research careers with adequate funding and clear 
career paths.
•  Re-establish the link between clinical medicine and basic 
research worldwide.
• Save the MD and PhD species from extinction.
• Develop eff orts to build up public confi dence.
•  Resist media blandishments to elevate hypotheses into 
impossible certainties.
•  Develop eff orts to identify and expose research fraud in 
industry-funded research.
•  Develop a better understanding of how to implement new 
medical developments and therapies.
•  Focus European framework programs on funding 
hypothesis-driven research and substantially decrease  
allocations for non-science-related issues.
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•  Th e European Council could play an important role in 
coordinating research funded by individual members to 
reduce duplication.
•  Reduce the shift  of top industrial research and development 
investment away from Europe by creating competitive 
clinical research centers in Europe.
(1Lancet 2006; 367: 1698–1701. 2Science 2006; 311: 1852–1854)
Marc De Broe
HIV-positive and -negative 
patients have similar survival rates 
after kidney transplantation
Patients positive for human immunodefi ciency virus 
(HIV) and renal failure were once thought to be unsuitable 
candidates for kidney transplantation. With the advent of 
highly active antiretroviral therapy and consequent control 
of HIV infection, reports of successful renal transplantation 
have been emerging.1 In an analysis of United Network for 
Organ Sharing data from 1997 to 2004, Qiu et al. show that 
HIV patients have success rates aft er transplantation equal to 
those of patients without HIV.2 Allograft  and patient survival 
of kidneys transplanted from the same donor into patients 
with and without HIV was compared. Th e 38 HIV-positive 
recipients were younger and had lower peak panel-reactive 
antibodies as compared with 38 HIV-negative recipients. 
Sirolimus was used more frequently in HIV patients than in 
non-HIV patients. Th e serum creatinine at 1, 3, and 5 years 
aft er transplantation was higher in HIV patients as compared 
with non-HIV patients. Although not to a statistically 
signifi cant degree, graft  survival and patient survival were 
higher among HIV-positive patients as compared with 
their negative controls. More graft s failed because of death 
with a functioning graft  than because of rejection in HIV-
positive patients. Th is study should remove any doubts about 
the ethics of performing transplantation in HIV-positive 
patients. (1Kidney Int 2005; 67: 1622–1629. 2Transplantation 
2006; 81: 1658–1661)
Jai Radhakrishnan
Targeting viral vectors to specific 
cell types in vivo
Gene therapy involves the introduction of a functional 
gene into a target cell to provide a therapeutic advantage. 
A particularly desirable gene therapy protocol would be to 
precisely deliver a gene of interest to specifi c cells or organs in 
vivo by means of administration of a designed gene delivery 
vehicle. Certain viruses are natural gene delivery systems, and 
much eff ort has been focused on engineering viral vectors 
as gene transfer vehicles. Among these vectors, ones derived 
from oncoretroviruses and lentiviruses exhibit promising 
features, because they have the ability to produce stable 
transduction, maintain long-term transgene expression, 
and, for lentiviruses, to transduce non-dividing cells. 
Targeting such viruses to particular cell types has proved to 
be challenging. Yang et al. now report a general method that 
allows such targeting.
Th e strategy involves uncoupling the target-cell recognition 
function from the fusion function by providing them in 
separate proteins. For recognition, the authors used antibodies, 
and for fusion, a viral glycoprotein that has been mutated to 
inactivate its binding ability. Th ey made lentiviral vectors that 
incorporate both molecules into their surface. Th e hypothesis 
was that the antibody should recognize a molecular constituent 
on the target-cell membrane and attach the lentivirus to 
the cell surface (see Figure). Antibody binding should then 
induce endocytosis, bringing the lentivirus into an endosome. 
Th ere, the fusogenic molecule (FM) should respond to the 
low-pH environment and trigger membrane fusion, allowing 
the virus core to enter the cytosol. Aft er reverse transcription 
and migration of the product to the nucleus, the genome 
of the vector should integrate into the target-cell genome, 
incorporating the vector’s transgene into the cell’s inheritance. 
Th us, the specifi city of such a lentiviral vector is solely 
determined by the antibody, which is chosen to recognize a 
specifi c surface antigen of the desired cell type.
By using CD20 as a target antigen for human B cells, the 
authors demonstrated that this targeting strategy is eff ective both 
in vitro and in intact animals. Th is methodology can be extended 
to other forms of cell type-specifi c recognition to mediate 
targeting; the only requirement is that the antibody (or other 
binding protein) must be endocytosed aft er interaction with its 
cell surface-binding determinant. (Proc Natl Acad Sci USA 2006; 
103: 11479–11484)
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